Tandem Diabetes Care (TNDM) to Release Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is anticipated to announce its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $277.1440 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $19.66 on Thursday. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33. Tandem Diabetes Care has a 1-year low of $9.98 and a 1-year high of $35.12. The firm has a market cap of $1.33 billion, a PE ratio of -6.45 and a beta of 1.68. The firm has a fifty day simple moving average of $21.10 and a two-hundred day simple moving average of $16.84.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TNDM. Natixis Advisors LLC increased its position in Tandem Diabetes Care by 1.1% during the 4th quarter. Natixis Advisors LLC now owns 57,021 shares of the medical device company’s stock worth $1,253,000 after purchasing an additional 617 shares in the last quarter. LPL Financial LLC increased its holdings in Tandem Diabetes Care by 1.8% in the 4th quarter. LPL Financial LLC now owns 39,590 shares of the medical device company’s stock valued at $870,000 after purchasing an additional 716 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Tandem Diabetes Care by 200.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company’s stock worth $27,000 after purchasing an additional 1,470 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Tandem Diabetes Care by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company’s stock valued at $1,426,000 after buying an additional 2,096 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in Tandem Diabetes Care by 5.7% in the second quarter. CANADA LIFE ASSURANCE Co now owns 56,332 shares of the medical device company’s stock valued at $1,051,000 after acquiring an additional 3,054 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group set a $35.00 price objective on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $30.00 price objective on shares of Tandem Diabetes Care and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Morgan Stanley set a $23.00 price objective on shares of Tandem Diabetes Care and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target on shares of Tandem Diabetes Care in a report on Friday, January 9th. Finally, Citigroup upped their price objective on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus target price of $24.35.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.